Table 2 Pathways used to generate pathway polygenic risk scores
From: GWAS for male-pattern baldness identifies 71 susceptibility loci explaining 38% of the risk
Pathway | Loci in pathway | N SNPs | SNP list |
|---|---|---|---|
Apoptosis | 1;32;64 | 4 | rs201089181;rs7542354;rs12203592;rs7226979 |
Apoptotic signalling pathway | 1;32;64 | 4 | rs201089181;rs7542354;rs12203592;rs7226979 |
Integrated pancreatic cancer pathway | 1;37;64;66 | 6 | rs201089181;rs7542354;rs9692245;rs62433864;rs7226979;rs17265513 |
Apoptosis modulation and signalling | 1;54;64 | 4 | rs201089181;rs7542354;rs417054;rs7226979 |
HIV-1 Nef: Negative effector of Fas and TNF-alpha | 1;64 | 3 | rs201089181;rs7542354;rs7226979 |
Caspase cascade in apoptosis | 1;64;66 | 4 | rs201089181;rs7542354;rs7226979;rs17265513 |
Prostate cancer—Homo sapiens (human) | 12;37;64;71 | 11 | rs534855217;rs191212334;rs577845405;rs534591951;rs13021718;rs9692245;rs62433864;rs7226979;rs4827528;rs113436165;rs7061504 |
Proteoglycans in cancer—Homo sapiens (human) | 19;21;38;57;60 | 9 | rs7349332;rs11684254;rs550618068;rs71530654;rs10225279;rs111931356;17_43947866;rs919462;rs572756998 |
ESC pluripotency pathways | 19;27;37;60 | 7 | rs7349332;rs7680591;rs9692245;rs62433864;17_43947866;rs919462;rs572756998 |
Pathways in cancer—Homo sapiens (human) | 19;27;37;60;64;68;71 | 12 | rs7349332;rs7680591;rs9692245;rs62433864;17_43947866;rs919462;rs572756998;rs7226979;rs68088846;rs4827528;rs113436165;rs7061504 |
Class B/2 (Secretin family receptors) | 19;51;60 | 5 | rs7349332;rs10843003;17_43947866;rs919462;rs572756998 |
Wnt signalling pathway | 19;54;60 | 5 | rs7349332;rs417054;17_43947866;rs919462;rs572756998 |
Wnt signalling pathway and pluripotency | 19;54;60 | 5 | rs7349332;rs417054;17_43947866;rs919462;rs572756998 |
WNT ligand biogenesis and trafficking | 19;60 | 4 | rs7349332;17_43947866;rs919462;rs572756998 |
Wnt signalling in kidney disease | 19;60 | 4 | rs7349332;17_43947866;rs919462;rs572756998 |
DNA damage response (only ATM dependent) | 19;60;64 | 5 | rs7349332;17_43947866;rs919462;rs572756998;rs7226979 |
Endochondral ossification | 2;25;34;51 | 7 | rs16830188;rs11249243;rs9803723;rs2064251;rs11714208;rs70993471;rs10843003 |
Regulation of nuclear SMAD2/3 signalling | 2;34;68;71 | 9 | rs16830188;rs11249243;rs9803723;rs2064251;rs70993471;rs68088846;rs4827528;rs113436165;rs7061504 |
TGF_beta_Receptor | 2;34;68;71 | 9 | rs16830188;rs11249243;rs9803723;rs2064251;rs70993471;rs68088846;rs4827528;rs113436165;rs7061504 |
Transcriptional misregulation in cancer—Homo sapiens (human) | 20;34;37;68 | 5 | rs77177529;rs70993471;rs9692245;rs62433864;rs68088846 |
Activation of the TFAP2 (AP-2) family of transcription factors | 3;67 | 3 | rs16827770;rs551865390;rs985546 |
White fat cell differentiation | 31;32 | 2 | rs1422798;rs12203592 |
Development of pulmonary dendritic cells and macrophage subsets | 32;34 | 2 | rs12203592;rs70993471 |
Notch-mediated HES/HEY network | 34;38;71 | 6 | rs70993471;rs71530654;rs10225279;rs4827528;rs113436165;rs7061504 |
Regulation of FZD by ubiquitination | 42;48 | 6 | rs182973285;rs16877149;rs77767830;rs79593277;rs530010717;rs79811440 |
Regulation of apoptosis by parathyroid hormone-related protein | 51;64 | 2 | rs10843003;rs7226979 |
Signalling by Wnt | 9;19;29;42;48;60 | 13 | rs78448052;rs7349332;rs73837363;rs76067940;rs182973285;rs16877149;rs77767830;rs79593277;rs530010717;rs79811440;17_43947866;rs919462;rs572756998 |
TCF-dependent signalling in response to WNT | 9;29;42;48;60 | 12 | rs78448052;rs73837363;rs76067940;rs182973285;rs16877149;rs77767830;rs79593277;rs530010717;rs79811440;17_43947866;rs919462;rs572756998 |
